BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 35637624)

  • 1. Effects of cannabidiol on simulated driving and cognitive performance: A dose-ranging randomised controlled trial.
    McCartney D; Suraev AS; Doohan PT; Irwin C; Kevin RC; Grunstein RR; Hoyos CM; McGregor IS
    J Psychopharmacol; 2022 Dec; 36(12):1338-1349. PubMed ID: 35637624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition.
    Arkell TR; Lintzeris N; Kevin RC; Ramaekers JG; Vandrey R; Irwin C; Haber PS; McGregor IS
    Psychopharmacology (Berl); 2019 Sep; 236(9):2713-2724. PubMed ID: 31044290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial.
    Arkell TR; Vinckenbosch F; Kevin RC; Theunissen EL; McGregor IS; Ramaekers JG
    JAMA; 2020 Dec; 324(21):2177-2186. PubMed ID: 33258890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of cannabidiol on simulated car driving performance: A randomised, double-blind, placebo-controlled, crossover, dose-ranging clinical trial protocol.
    McCartney D; Benson MJ; Suraev AS; Irwin C; Arkell TR; Grunstein RR; Hoyos CM; McGregor IS
    Hum Psychopharmacol; 2020 Sep; 35(5):e2749. PubMed ID: 32729120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of CannEpil
    Manning B; Hayley AC; Catchlove S; Shiferaw B; Stough C; Downey LA
    J Psychopharmacol; 2023 May; 37(5):472-483. PubMed ID: 37129083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users.
    Spindle TR; Cone EJ; Goffi E; Weerts EM; Mitchell JM; Winecker RE; Bigelow GE; Flegel RR; Vandrey R
    Drug Alcohol Depend; 2020 Jun; 211():107937. PubMed ID: 32247649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial.
    Schoedel KA; Szeto I; Setnik B; Sellers EM; Levy-Cooperman N; Mills C; Etges T; Sommerville K
    Epilepsy Behav; 2018 Nov; 88():162-171. PubMed ID: 30286443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised controlled trial of vaporised Δ
    Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
    Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orally administered cannabidiol does not produce false-positive tests for Δ
    McCartney D; Kevin RC; Suraev AS; Irwin C; Grunstein RR; Hoyos CM; McGregor IS
    Drug Test Anal; 2022 Jan; 14(1):137-143. PubMed ID: 34412166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double-blind, placebo-controlled, crossover experiment.
    Lawn W; Trinci K; Mokrysz C; Borissova A; Ofori S; Petrilli K; Bloomfield M; Haniff ZR; Hall D; Fernandez-Vinson N; Wang S; Englund A; Chesney E; Wall MB; Freeman TP; Curran HV
    Addiction; 2023 Jul; 118(7):1282-1294. PubMed ID: 36750134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios.
    Englund A; Oliver D; Chesney E; Chester L; Wilson J; Sovi S; De Micheli A; Hodsoll J; Fusar-Poli P; Strang J; Murray RM; Freeman TP; McGuire P
    Neuropsychopharmacology; 2023 May; 48(6):869-876. PubMed ID: 36380220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of four-week cannabidiol treatment on cognitive function: secondary outcomes from a randomised clinical trial for the treatment of cannabis use disorder.
    Lees R; Hines LA; Hindocha C; Baio G; Shaban NDC; Stothart G; Mofeez A; Morgan CJA; Curran HV; Freeman TP
    Psychopharmacology (Berl); 2023 Feb; 240(2):337-346. PubMed ID: 36598543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis.
    Haney M; Malcolm RJ; Babalonis S; Nuzzo PA; Cooper ZD; Bedi G; Gray KM; McRae-Clark A; Lofwall MR; Sparenborg S; Walsh SL
    Neuropsychopharmacology; 2016 Jul; 41(8):1974-82. PubMed ID: 26708108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating possible 'next day' impairment in insomnia patients administered an oral medicinal cannabis product by night: a pilot randomized controlled trial.
    Suraev A; McCartney D; Marshall NS; Irwin C; Vandrey R; Grunstein RR; D'Rozario AL; Gordon C; Bartlett D; Hoyos CM; McGregor IS
    Psychopharmacology (Berl); 2024 May; ():. PubMed ID: 38758300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial.
    Grimison P; Mersiades A; Kirby A; Lintzeris N; Morton R; Haber P; Olver I; Walsh A; McGregor I; Cheung Y; Tognela A; Hahn C; Briscoe K; Aghmesheh M; Fox P; Abdi E; Clarke S; Della-Fiorentina S; Shannon J; Gedye C; Begbie S; Simes J; Stockler M
    Ann Oncol; 2020 Nov; 31(11):1553-1560. PubMed ID: 32801017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How long does a single oral dose of cannabidiol persist in plasma? Findings from three clinical trials.
    McCartney D; Kevin RC; Suraev AS; Sahinovic A; Doohan PT; Bedoya-Pérez MA; Grunstein RR; Hoyos CM; McGregor IS
    Drug Test Anal; 2023 Mar; 15(3):334-344. PubMed ID: 36478641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol.
    Bhardwaj AK; Mills L; Doyle M; Sahid A; Montebello M; Monds L; Arunogiri S; Haber P; Lorenzetti V; Lubman DI; Malouf P; Harrod ME; Dunlop A; Freeman T; Lintzeris N
    BMC Psychiatry; 2024 Mar; 24(1):175. PubMed ID: 38433233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The failings of
    Arkell TR; Spindle TR; Kevin RC; Vandrey R; McGregor IS
    Traffic Inj Prev; 2021; 22(2):102-107. PubMed ID: 33544004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users.
    Hindocha C; Freeman TP; Schafer G; Gardener C; Das RK; Morgan CJ; Curran HV
    Eur Neuropsychopharmacol; 2015 Mar; 25(3):325-34. PubMed ID: 25534187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using alcohol intoxication goggles (Fatal Vision® goggles) to detect alcohol related impairment in simulated driving.
    McCartney D; Desbrow B; Irwin C
    Traffic Inj Prev; 2017 Jan; 18(1):19-27. PubMed ID: 27260944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.